Physician

Rachit Kumar, M.D.

According to 2025 Medicare claims, Rachit Kumar, M.D. (NPI: 1316258148) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Henrico, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23229-8605. Kumar is affiliated with the MaineHealth Accountable Care Organization (ACO ID: A1290), participating under the MSSP model.

Kumar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 780 traditional Medicare patients, billed 127,204 HCPCS/CPT codes, and received $2,684,329 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 923 prescription claims across 166 beneficiaries totaling $1,952,527 in drug costs, led by Revlimid (Lenalidomide). DME data shows 97 claims. Open Payments data shows 77 records totaling $62,898. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $25,021 to $2,684,329. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	236	370	$25,021
2018	504	1,307	$79,456
2019	391	1,096	$69,410
2020	353	1,107	$72,396
2021	282	786	$60,575
2022	253	900	$70,102
2023	702	93,170	$1,492,271
2024	780	127,204	$2,684,329

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	11	28	$5,693
2017	67	179	$133,541
2018	216	1,006	$2,316,954
2019	316	1,288	$3,124,981
2020	312	1,413	$3,137,603
2021	309	1,309	$3,502,311
2022	281	1,185	$3,826,094
2023	244	807	$1,987,714
2024	166	923	$1,952,527

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	35	$737
2018	N/R	240	$11,714
2019	33	356	$21,654
2020	33	341	$18,831
2021	N/R	166	$7,439
2022	N/R	112	$7,186
2023	N/R	131	$9,054
2024	N/R	97	$5,644

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	142	336	$103
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	221	550	$101
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	134	181	$65
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	192	289	$13
96372	Injection of drug or substance under skin or into muscle	140	312	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	52	1,446	$973,696
Calquence	Acalabrutinib Maleate	11	330	$170,704
Eliquis	Apixaban	70	3,540	$66,882
Orgovyx	Relugolix	18	535	$48,872
Xarelto	Rivaroxaban	20	1,380	$24,899

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	36	$2,221
E0781	Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient	Y	N/R	11	$1,774
J9190	Injection, fluorouracil, 500 mg	N	N/R	36	$945
J8521	Capecitabine, oral, 500 mg	N	N/R	14	$704

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	75	$1,646	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$61,251	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rachit Kumar, M.D.?

Tedicare shows public-source Medicare data for Rachit Kumar, M.D. (NPI 1316258148), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rachit Kumar, M.D. have ACO affiliation data?

Rachit Kumar, M.D. is shown with ACO affiliation data for MaineHealth Accountable Care Organization (MSSP, ACO ID A1290).

What billing organization is linked to Rachit Kumar, M.D.?

Rachit Kumar, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Rachit Kumar, M.D. have Open Payments data?

Rachit Kumar, M.D. has 77 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.